537 results on '"Mrugala, Maciej"'
Search Results
152. NIMG-61. USING MACHINE LEARNING TO BUILD RADIOMICS MODELS THAT DISTINGUISH REGIONS OF GLIOBLASTOMA RECURRENCE VS TUMOR PROGRESSION ON MRI
153. NIMG-52. UNCERTAINTY QUANTIFICATION IN RADIOMICS
154. NIMG-58. SEX DIFFERENCES IN CONTRAST-ENHANCING GLIOMAS AT PRESENTATION
155. TMOD-15. IDENTIFYING THE SPATIAL AND TEMPORAL DYNAMICS OF GLIOBLASTOMA SUBPOPULATIONS WITHIN INDIVIDUAL PATIENTS
156. Days Gained Response Discriminates Treatment Response in Patients with Recurrent Glioblastoma Receiving Bevacizumab-based Therapies
157. Sex differences in seizure at presentation in glioma population
158. ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma
159. Sex Differences in Predictors of Seizure in Contrast-Enhancing Gliomas at Clinical Presentation: A Network Approach
160. Clinical evaluation of fitness to drive in patients with brain metastases
161. Sex Matters in Health and Disease: a review of biological sex differences with an emphasis on glioma
162. Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines
163. Psychiatric Disturbance As a Presenting Symptom in Central Nervous System Lymphoma (P1.6-011)
164. Successful monitoring and treatment of neurotoxicity in a patient treated with CAR-T-cell therapy enhanced by ocular ultrasound (P3.9-022)
165. The Use of Recombinant Poliovirus for the Treatment of Recurrent Glioblastoma Multiforme
166. Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma
167. Management of leptomeningeal disease from solid tumors
168. A Review on Tumor-Treating Fields (TTFields):Clinical Implications Inferred from Computational Modeling
169. LZTR1‐related spinal schwannomatosis and 7q11.23 duplication syndrome: A complex phenotype with dual diagnosis.
170. Troubleshooting an unusual complication following intrathecal chemotherapy delivered via Ommaya catheter: A case report.
171. Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma
172. ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: a Multi-disciplinary Team-based, Multifactorial Analytical Approach
173. CMET-24. NEXT-GENERATION EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR LEPTOMENINGEAL CARCINOMATOSIS
174. NIMG-06. KINETICS-BASED RESPONSE METRIC DISCRIMINATE IMPROVED OUTCOMES FOR PATIENTS RECEIVING BEVACIZUMAB-BASED THERAPIES
175. NIMG-16. IMPACT OF SEX DIFFERENCES AND TUMOR LOCATION ON SURVIVAL OUTCOMES IN GLIOBLASTOMA PATIENTS
176. CMET-47. CLINICAL EVALUATION OF FITNESS TO DRIVE IN PATIENTS WITH BRAIN METASTASES
177. PATH-12. CHARACTERISTICS OF GIANT CELL MORPHOLOGY IN LONG-TERM SURVIVORS OF GLIOBLASTOMA: CONSIDERATION OF SEX DIFFERENCES
178. NIMG-21. SEX DIFFERENCES IN EXTREME SURVIVORSHIP AMONG PRIMARY GLIOBLASTOMA PATIENTS
179. NIMG-19. SEX-SPECIFIC BRAIN MAPS FOR RISK OF SEIZURE AMONG GLIOMA PATIENTS
180. CAR-T cell therapy in neuro-oncology: applications and toxicity
181. Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
182. Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients
183. Neuro-oncologists have spoken – the role of bevacizumab in the inpatient setting. A clinical and economic conundrum
184. CASPR2 Autoimmunity Preceding the Diagnosis of Thyroid Cancer (P6.099)
185. Clinical evaluation of fitness to drive in patients with brain metastases (P6.151)
186. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling
187. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
188. NIMG-93. DISCRIMINATION OF CLINICALLY IMPACTFUL TREATMENT RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING BEVACIZUMAB TREATMENT
189. NIMG-44. ROLE OF PRE-TREATMENT TUMOR DYNAMICS AND IMAGING RESPONSE IN DISCRIMINATING GLIOBLASTOMA SURVIVAL FOLLOWING GAMMA KNIFE
190. NIMG-11. IDENTIFYING EARLY INDICATORS OF IMMUNOTHERAPEUTIC RESPONSE: CAR T-CELL THERAPY
191. TMOD-38. EXTENT OF GLIOBLASTOMA INVASION PREDICTS OVERALL SURVIVAL FOLLOWING UPFRONT RADIOTHERAPY CONCURRENT WITH TEMOZOLOMIDE
192. Inpatient Use of Bevacizumab in Neuro-Oncology Patients – Challenges and Practice (P1.171)
193. When the Imaging is No Help – A Rare Presentation of Primary CNS Lymphoma (P3.163)
194. Prognosis of older patients with low-grade glioma: A retrospective study
195. Corrigendum to 'Clinical Practice Experience With Novo TTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)' Seminars in Oncology, Vol 41, No 5, Suppl 6,October 2014, pp S4-S13
196. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma
197. Psychiatric Disturbance or Parkinsonism as a Presentation of CNS Lymphoma: Observational Retrospective Study and Review of Literature
198. Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer
199. Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.
200. Neuro-oncologists have spoken – the role of bevacizumab in the inpatient setting. A clinical and economic conundrum.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.